» Articles » PMID: 33347984

Cross Your Heart? Collagen Cross-links in Cardiac Health and Disease

Overview
Journal Cell Signal
Date 2020 Dec 21
PMID 33347984
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular matrix (ECM) remodeling occurs in response to various cardiac insults including infarction, pressure overload and dilated myopathies. Each type of remodeling necessitates distinct types of ECM turnover and deposition yet an increase in myocardial fibrillar collagen content is appreciated as a contributing feature to cardiac dysfunction in each of these pathologies. In addition, aging, is also associated with increases in cardiac collagen content. The importance of characterizing differences in ECM composition and processes used by cardiac fibroblasts in the assembly of fibrotic collagen accumulation is critical for the design of strategies to reduce and ultimately regress cardiac fibrosis. Collagen cross-linking is one factor that influences collagen deposition and insolubility with direct implications for tissue properties such as stiffness. In this review, three different types of collagen cross-links shown to be important in cardiac fibrosis will be discussed; those catalyzed by lysyl oxidases, those catalyzed by transglutaminases, and those that result from non-enzymatic modification by the addition of advanced glycation end products. Insight into cellular mechanisms that govern collagen cross-linking in the myocardium will provide novel pathways for exploring new treatments to treat diseases associated with cardiac fibrosis.

Citing Articles

The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

Skorka P, Piotrowski J, Bakinowska E, Kielbowski K, Pawlik A Rev Cardiovasc Med. 2025; 26(2):27152.

PMID: 40026508 PMC: 11868901. DOI: 10.31083/RCM27152.


Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5.

Behounek M, Lipcseyova D, Vit O, Zacek P, Talacko P, Huskova Z Circ Heart Fail. 2025; :e011984.

PMID: 39823288 PMC: 11905906. DOI: 10.1161/CIRCHEARTFAILURE.124.011984.


Matrix Architecture and Mechanics Regulate Myofibril Organization, Costamere Assembly, and Contractility in Engineered Myocardial Microtissues.

DePalma S, Jilberto J, Stis A, Huang D, Lo J, Davidson C Adv Sci (Weinh). 2024; 11(47):e2309740.

PMID: 39558513 PMC: 11653763. DOI: 10.1002/advs.202309740.


Use of Hydrogels in Regenerative Medicine: Focus on Mechanical Properties.

Carton F, Rizzi M, Canciani E, Sieve G, Di Francesco D, Casarella S Int J Mol Sci. 2024; 25(21).

PMID: 39518979 PMC: 11545898. DOI: 10.3390/ijms252111426.


Glycation in the cardiomyocyte.

Delligatti C, Kirk J Vitam Horm. 2024; 125:47-88.

PMID: 38997172 PMC: 11578284. DOI: 10.1016/bs.vh.2024.04.005.


References
1.
Joshi A, Zahoor A, Buson A . Measurement of Collagen Cross-Links from Tissue Samples by Mass Spectrometry. Methods Mol Biol. 2019; 1944:79-93. DOI: 10.1007/978-1-4939-9095-5_6. View

2.
Maki J, Rasanen J, Tikkanen H, Sormunen R, Makikallio K, Kivirikko K . Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 2002; 106(19):2503-9. DOI: 10.1161/01.cir.0000038109.84500.1e. View

3.
Shinde A, Su Y, Palanski B, Fujikura K, Garcia M, Frangogiannis N . Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. J Mol Cell Cardiol. 2018; 117:36-48. PMC: 5892840. DOI: 10.1016/j.yjmcc.2018.02.016. View

4.
Umana-Diaz C, Pichol-Thievend C, Marchand M, Atlas Y, Salza R, Malbouyres M . Scavenger Receptor Cysteine-Rich domains of Lysyl Oxidase-Like2 regulate endothelial ECM and angiogenesis through non-catalytic scaffolding mechanisms. Matrix Biol. 2019; 88:33-52. DOI: 10.1016/j.matbio.2019.11.003. View

5.
Ciulla M, Paliotti R, Carini M, Magrini F, Aldini G . Fibrosis, Enzymatic and Non-Enzymatic Cross-Links in Hypertensive Heart Disease. Cardiovasc Hematol Disord Drug Targets. 2011; 11(2):61-73. DOI: 10.2174/187152911798347025. View